Lexaria Bioscience Corp. Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction With CBD

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug-delivery platforms, has announced that its human clinical study HYPER-H21-2, which features LEXX’s patented DehydraTECH(TM)-processed cannabidiol (“CBD”), demonstrates up to a 23% decrease in blood pressure when compared to a placebo.

According to the announcement, partial results were released on Tuesday with additional blood pressure subset analyses, sleep quality and all other data analyses will be reported when complete.

Partial results indicate that at selected times during the 24-hour study, volunteers with mild to moderate hypertension averaged as much as a 20 …

Full story available on Benzinga.com

More Lexaria Bioscience Corp. Releases Results Of Human Clinical Study Showing Effective, Safe BP Reduction With CBD